CD274 and neoplasm: Based on these studies, we aimed to explore whether PD-L1 can be efficiently targeted by the TCR-T-based platform to mitigate the PD-1/PD-L1 mediated inhibition of TIL and to lyse tumor cells, ultimately eliminating solid tumors.